Additional file 1 of A four-stage model for murine natural killer cell development in vivo

Additional file 1. Figure S1. Functional characteristics of four developmental stages of murine NK cells

Additional file 2 of A four-stage model for murine natural killer cell development in vivo

Additional file 2. Materials and Methods

Supplementary Materials and Methods from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <i>Ex Vivo</i>–Expanded Autologous NK Cells

Supplementary materials and methods</p

Supplementary Figure S1-S15 from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by <i>Ex Vivo</i>–Expanded Autologous NK Cells

Supplementary Figure S1: Dara induces IFN-gamma expression in primary human NK cells; Supplementary Figure S2: MM.1S surface expression of CD38 was assessed by flow cytometry; Supplementary Figure S3: Dara promotes NK-mediated ADCC of MM.1S target cells, which correlates to activation of STAT1 and NF-kB signaling; Supplementary Figure S4: Dara fails to increase apoptosis or IFNG expression in CD16(-) NK-92 cells; Supplementary Figure S5: Reduction in relative proportion of NK cells occurs in both peripheral blood and bone marrow of Dara-treated MM patients; Supplementary Figure S6: Dara increases primary NK cell death; Supplementary Figure S7: Separation of daratumumab into F(ab')2 and Fc fragments; Supplementary Figure S8: CD38^â^'/low primary NK cells show lower apoptotic activity than CD38^+ primary NK cells; Supplementary Figure S9: Compared to their CD38^+ counterparts, the CD38^â^'/low subset of NK cells from peripheral blood of healthy donors are more proliferative and have higher levels of cytotoxicity against MM targets; Supplementary Figure S10: Competition between CD38^+ exp. NK cells and MM cells for Dara binding during co-culture; Supplementary Figure S11: Differential expression of surface receptors within CD38^+ and CD38^â^'/low subsets of NK cells; Supplementary Figure S12: Differential expression of GZMB in CD38^+ and CD38^â^'/low NK subsets found within populations of CD56^bright and CD56^dim NK cells; Supplementary Figure S13: Purity of in vitro-expanded NK cells at day 7; Supplementary Figure S14: NK cells expanded (eNK) from Dara-treated MM patient PBMCs show anti-tumor efficacy against MM in an in vivo mouse model; Supplementary Figure S15: Treatment of MM-bearing mice with or without Dara, expanded NK cells (eNK), or their combination.</p

Supplementary Data from The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Supplementary figures and figure legends as well as supplementary methods and materials</p

Supplementary Figures 1-11 and Supplementary Tables 1-2 from Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model

Supplementary Fig. 1. Mice treated with CCL2 neutralizing antibody (nab) for 4 weeks did not show significant changes in body weight; Supplementary Fig. 2. CCR2 inhibitor therapy reduces chronic liver inflammation in miR-122 knockout (KO) mouse; Supplementary Fig. 3. CCL2 nab therapy did not reduce CD11bhighGr1+ inflammatory myeloid cells in the peripheral blood; Supplementary Fig. 4. Blocking the CCL2-CCR2 axis reduces hepatic macrophages; Supplementary Fig. 5. CCL2 nab does not alter the population of B cell, T cell, and NK cell in liver; Supplementary Fig. 6. CCR2 inhibitor therapy reduces CD11bhighGr1+ inflammatory cells in the KO mouse liver; Supplementary Fig. 7. 12-month-old male KO mice were assigned to vehicle and CCL2 nab treated groups based on serum AFP and body weight; Supplementary Fig. 8. CCL2 immunotherapy reduces tumoral p-STAT3, c-MYC, and p65 levels. Supplementary Fig. 9. CCL2 immunotherapy reduces the number of proliferative cells in the adjacent benign tumors; Supplementary Fig. 10. Blocking CCL2 by neutralizing antibody increases cell apoptosis; Supplementary Fig. 11 CCL2 nab therapy inhibits HCC development in KO mice by modulating tumor microenvironment; Supplementary Table 1. Primers used for RT-qPCR analysis; Supplementary Table 2. Serological analysis of 4 months old KO mice.</p

Supplementary Figures 1-4 from Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype

Figure S1. Mouse characteristics prior to tumor injection and at time of sacrifice. Figure S2.Mouse physiology following EE Figure S3. Overexpressing BDNF in the hypothalamus mimics EE's effects on T cells. Figure S4. Knockdown BDNF in the hypothalamus blocks EE's effects.</p

Supplementary Data from Oncolytic HSV–Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition

Supplementary Table</p

Figure S1 from A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Protein design of control biAb with CDR3 deleted on the anti-NKG2D scFv</p

Supplementary Data from Oncolytic HSV–Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition

Supplementary Methods and Supplementary Figure Legends</p